← Human Trials & Peer-Reviewed Studies
Clinical trial of the effects of vitamin D supplementation on psychological symptoms and metabolic profiles in maintenance methadone treatment patients.
Plain-language guide to PMID 28642082 (2017): double-blind randomized controlled trial of Vitamin D, K2, Magnesium and Zinc in 68 patients.
Key Facts
- PMID
- 28642082
- Journal
- Progress in neuro-psychopharmacology & biological psychiatry
- Year
- 2017
- Study type
- Randomized Controlled Trial
- Authors
- Ghaderi A et al. (6 authors)
- DOI
- 10.1016/j.pnpbp.2017.06.016
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Vitamin D, K2, Magnesium and Zinc, published as a randomized controlled trial.
This study was designed to determine the effect of vitamin D supplementation on psychological symptoms and metabolic profiles in MMT patients.
Fasting blood samples were taken at baseline and post-intervention to evaluate relevant variables.
Who Took Part
The study group was 68 patients.
PubMed indexes the participants as adults.
This randomized, double-blind, placebo-controlled, clinical trial was carried out among 68 MMT patients.
How the Study Was Run
The design is described as randomized, double-blind and placebo-controlled.
Because people in this Vitamin D, K2, Magnesium and Zinc study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
As a double-blind Vitamin D, K2, Magnesium and Zinc study, the assignments were hidden from both participants and investigators until the end.
A placebo (an inactive look-alike) gave the Vitamin D, K2, Magnesium and Zinc group a baseline to be compared against.
What Was Measured
The subject headings attached to it are Biomarkers, Dietary Supplements, Methadone, Narcotics, Opioid-Related Disorders and Vitamin D.
The authors tagged it with the keywords Maintenance methadone treatment, Metabolic profiles, Psychological symptoms and Vitamin D supplementation.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in 68 patients.
The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2017 (Progress in neuro-psychopharmacology & biological psychiatry), a journal based in England.
More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.
Our Notes on the Compound
Vitamin D, K2, Magnesium and Zinc: Magnesium is described as required for AMPK to function.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.